UK group Reckitt & Colman is believed to be planning a marketing jointventure with British company Nicholas Piramal to cover its pharmaceutical product range. It is expected to include Reckitt and Colman India products such as its anti-epilepsy drugs and antiseptics. Pharmaceutical sales accounted for approximately 10% of RCI turnover in 1996.
Although senior management at Nicholas and RCI declined to comment on the project, sources at RCI claim talks have been underway for some two months, and it is known that Nicholas wishes to develop its over-the-counter business in India.
As a result of its merger with Piramal Healthcare, Nicholas now has access to best-selling Hoffman-La Roche brands such as Saridon, Aspro, Cleartone and Vitaminets Forte.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze